Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Effectiveness of a cardiovascular health EHR application for cancer survivors in community oncology practice

Prof Kathryn Weaver - Wake Forest School of Medicine, Winston-Salem, USA
Effectiveness of a cardiovascular health EHR application for cancer survivors in community oncology practice ( Prof Kathryn Weaver - Wake Forest School of Medicine, Winston-Salem, USA )
5 Jun 2023

Sintilimab plus chemo shows promise in high-risk locoregionally-advanced nasopharyngeal carcinoma

Prof Jun Ma - Sun Yat-sen University Cancer Center, Guangzhou, China
Sintilimab plus chemo shows promise in high-risk locoregionally-advanced nasopharyngeal carcinoma ( Prof Jun Ma - Sun Yat-sen University Cancer Center, Guangzhou, China )
5 Jun 2023

ASCO 2023: Head and neck highlights

Dr Glenn Hanna - Dana-Farber Cancer Institute, Boston, USA
ASCO 2023: Head and neck highlights ( Dr Glenn Hanna - Dana-Farber Cancer Institute, Boston, USA )
5 Jun 2023

Cabozantinib with nivolumab/ipilimumab shows superior efficacy compared to cabozantinib alone in soft tissue sarcoma

Dr Brian Van Tine - Washington University in St Louis, St Louis, USA
Cabozantinib with nivolumab/ipilimumab shows superior efficacy compared to cabozantinib alone in soft tissue sarcoma ( Dr Brian Van Tine - Washington University in St Louis, St Louis, USA )
5 Jun 2023

Baseline liquid biopsy results in treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC

Prof Sebastian Stintzing - Universitätsmedizin Berlin, Berlin, Germany
Baseline liquid biopsy results in treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC ( Prof Sebastian Stintzing - Universitätsmedizin Berlin, Berlin, Germany )
4 Jun 2023

Real-world behavioural restrictional practices of cancer patients

Dr Eliya Shahar - Tel Aviv University, Tel Aviv, Israel
Real-world behavioural restrictional practices of cancer patients ( Dr Eliya Shahar - Tel Aviv University, Tel Aviv, Israel )
4 Jun 2023

Elranatamab shows efficacy in RRMM with prior BCMA-directed treatment

Prof Ajay Nooka - Winship Cancer Center of Emory University, Atlanta, USA
Elranatamab shows efficacy in RRMM with prior BCMA-directed treatment ( Prof Ajay Nooka - Winship Cancer Center of Emory University, Atlanta, USA )
4 Jun 2023

Pembrolizumab improves OS in firstline treatment for unresectable advanced pleural mesothelioma

Dr Penelope Bradbury - Princess Margaret Cancer Centre, Toronto, Canada
Pembrolizumab improves OS in firstline treatment for unresectable advanced pleural mesothelioma ( Dr Penelope Bradbury - Princess Margaret Cancer Centre, Toronto, Canada )
4 Jun 2023

Pembro plus chemo followed by resection and adjuvant pembro improves on standard of care for early NSCLC

Prof Heather Wakelee - Stanford Cancer Institute, Stanford, USA
Pembro plus chemo followed by resection and adjuvant pembro improves on standard of care for early NSCLC ( Prof Heather Wakelee - Stanford Cancer Institute, Stanford, USA )
4 Jun 2023

Nivolumab-AVD reduces the risk of disease progression compared to brentuximab vedotin-AVD in advanced Hodgkin lymphoma

Dr Alex Herrera - City of Hope Comprehensive Cancer Center, Duarte, USA
Nivolumab-AVD reduces the risk of disease progression compared to brentuximab vedotin-AVD in advanced Hodgkin lymphoma ( Dr Alex Herrera - City of Hope Comprehensive Cancer Center, Duarte, USA )
4 Jun 2023

PHE885 CAR-T cell therapy shows high response rates for r/r multiple myeloma in phase 1

Prof Adam Sperling - Dana-Farber Cancer Institute, Boston, USA
PHE885 CAR-T cell therapy shows high response rates for r/r multiple myeloma in phase 1 ( Prof Adam Sperling - Dana-Farber Cancer Institute, Boston, USA )
4 Jun 2023

HCC: Improvement in RFS for atezolizumab plus bevacizumab vs active surveillance without compromising QoL

Prof Masatoshi Kudo - Kindai University, Higashiōsaka, Japan
HCC: Improvement in RFS for atezolizumab plus bevacizumab vs active surveillance without compromising QoL ( Prof Masatoshi Kudo - Kindai University, Higashiōsaka, Japan )
4 Jun 2023